Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6490848 | 0.92 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5608707 | 0.87 | MAPK8 (0.52) | MAPK8ADRA2AADRA2BADRA2CPTGER4 | |
| SCHEMBL5373538 | 0.84 | MAPK8 (0.50) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5388428 | 0.82 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5397426 | 0.82 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5392732 | 0.82 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5381681 | 0.80 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5388749 | 0.80 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5388761 | 0.80 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DMAPK8 | |
| SCHEMBL5381658 | 0.80 | PDE4A (0.61) | PDE4APDE4BPDE4CPDE4DMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953810-B2 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-10-11 | — | — | US | disclosed |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2004-03-11 | — | — | US | disclosed |
| US-6649633-B2 | For treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-11-18 | — | — | US | disclosed |
| EP-1355884-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002060875-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193612-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | PDE4A 13/4885PDE4B 12/4885PDE4C 36/4885 |
| US-20040048903-A1 | Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, NOX1 | PDE4A 16/4885PDE4B 14/4885PDE4C 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.